

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 2005_1543A	SERIAL NO. NEW	<b>10/551138</b>		
LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)			APPLICANT Dimitrios E. LIZOS et al.				
Date Submitted to PTO: September 29, 2005			FILING DATE September 29, 2005		GROUP		
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
B JD	AA	3,539,631	11/1970	Pallos et al.			
	AB						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
B JD	AC	99/04778	2/1999	WO			
	AD	96/29316	9/1996	WO			
	AE	0 011 182	5/1980	EP			X
	AF						
	AG						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
B JD	AH	Database Registry, Chemical Abstracts Service, April 12, 1986, Chemical Abstracts: RN 101398-76-9, XP002287521, Abstract.					
	AI	Frank P. Bymaster et al., "Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)-6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane", European Journal of Pharmacology, Vol. 356, No. 2-3, September 4, 1998, pp. 109-119.					
	AJ	S. M. Cochran et al., "Induction of differential patterns of local cerebral glucose metabolism and immediate-early genes by acute clozapine and haloperidol", Neuropharmacology, Vol. 43, No. 3, September 2002, pp. 394-407.					
	AK	B. Pouzet et al., "Effects of the 5-HT <sub>2</sub> receptor antagonist SB-258741 in animal models for schizophrenia", Pharmacology, Biochemistry and Behavior, Vol. 71, No. 4, April 2002, pp. 655-665.					
	AL						
	AM						
EXAMINER			DATE CONSIDERED		10/15/07		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.